<SEC-DOCUMENT>0001558370-21-012970.txt : 20211004
<SEC-HEADER>0001558370-21-012970.hdr.sgml : 20211004
<ACCEPTANCE-DATETIME>20211004131431
ACCESSION NUMBER:		0001558370-21-012970
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20211001
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211004
DATE AS OF CHANGE:		20211004

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Xencor Inc
		CENTRAL INDEX KEY:			0001326732
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				201622502
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36182
		FILM NUMBER:		211301800

	BUSINESS ADDRESS:	
		STREET 1:		111 WEST LEMON AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		626-305-5900

	MAIL ADDRESS:	
		STREET 1:		111 WEST LEMON AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>xncr-20211001x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7908.23199 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 10/4/2021 5:09:40 PM -->
      <!-- iXBRL Library version: 1.0.7908.23207 -->
      <!-- iXBRL Service Job ID: 99d2c126-4bdb-49ff-905a-9f6507da65f4 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xncr="http://www.xencor.com/20211001" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" name="dei:EntityCentralIndexKey" id="Tc_gphqhG1GeUuh2NS0KI5ZEA_2_1">0001326732</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" name="dei:AmendmentFlag" id="Tc_5_LMAeMA3kubrPNLCC93zw_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="xncr-20211001.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326732</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:15.52pt;"><a id="_f6c657c9_8ad4_45d8_8bf8_c7062c1956a1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p><div style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;">FORM&#160;<ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" name="dei:DocumentType" id="Narr_EDgK3i7Lx0atiQxZaALo0g">8-K</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p><div style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">of The Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:10pt;">Date of Report (Date of earliest event reported):</span><b style="font-size:10pt;font-weight:bold;">&#160; </b><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_yY-OjCvTEEaezaiwstrwnQ"><b style="font-size:10pt;font-weight:bold;">October 1, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:2pt;line-height:1.19;margin:0pt;">&#160;</p><div style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" name="dei:EntityRegistrantName" id="Narr_XIZcNPqU2kadIe1iep93Hw">XENCOR,&#160;INC.</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p><div style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_204a99bf_9232_418a_b7bf_9ca53e35033c"></a><a id="Tc_QvHrNoyjdk2s_FZxbmF4iQ_3_0"></a><a id="Tc_H8rhrpEgjkuJ801FfNCuuw_3_2"></a><a id="Tc_MJEiCjAn70SqrDA-qydiuw_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_9SAcT6RcHEuQy8mVbOnESw_2_0"><b style="font-size:10pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" name="dei:EntityFileNumber" id="Tc_0-adsj4q60-JTb294GIMqw_2_2"><b style="font-size:10pt;font-weight:bold;">001-36182</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" name="dei:EntityTaxIdentificationNumber" id="Tc_r5z8mT8tA0iFffIfF5lebw_2_4"><b style="font-size:10pt;font-weight:bold;">20-1622502</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Commission File Number)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(IRS Employer Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><span style="font-size:5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_e777fc37_2718_4bf1_b871_2d94d12e4f7d"></a><a id="Tc_QFzNaRDsFUeM25isyZJdbQ_0_0"></a><a id="Tc_iWeUP49rAUSe2RL-scNlmA_1_0"></a><a id="Tc_dQTqOSsuF0yFIDdCuvk4hA_2_0"></a><a id="Tc_42xBuYU4gUqrA72A8v-fYQ_2_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;line-height:1;">111 West Lemon Avenue</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:38.7pt;"><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" name="dei:EntityAddressAddressLine1" id="Narr_Din-X3k4m0SRcR0AFp3zgg"><b style="font-size:10pt;font-weight:bold;">111 West Lemon Avenue</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" name="dei:EntityAddressCityOrTown" id="Narr_UDp-RF92SkqEchcbkh1MFw"><b style="font-size:10pt;font-weight:bold;">Monrovia</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_AfHr_9oTaEeCKFIu96deWg"><b style="font-size:10pt;font-weight:bold;">California</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;text-indent:9pt;margin:12pt 0pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" name="dei:EntityAddressPostalZipCode" id="Tc_CskCa4pPekekgp4I9cvelw_1_1"><b style="font-size:10pt;font-weight:bold;">91016</b></ix:nonNumeric></p></td></tr><tr style="height:3.7pt;"><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:9pt;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:10pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" name="dei:CityAreaCode" id="Narr_Ms8OguH7802T47BNJetrQQ"><b style="font-size:10pt;font-weight:bold;">626</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" name="dei:LocalPhoneNumber" id="Narr_T1uPBKMnR0mYndl3f5r-FQ"><b style="font-size:10pt;font-weight:bold;">305-5900</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code) </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Former name or former address, if changed since last report.) </p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;line-height:1.19;margin:0pt;">&#160;</p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="text-decoration:underline;text-decoration-color:#000000;">see</span> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk12624516"></a><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_UCw0dtQqhU6hxQ_c5bipfw"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric><span style="font-size:10pt;">&#160;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_LrbClwsJMEm84IFytWhLGA"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric><span style="font-size:10pt;">&#160;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_HZMxVBmQR02kT6EwJWggTA"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric><span style="font-size:10pt;">&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_9TOKdo-vnECAnT9IzMMrCQ"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric><span style="font-size:10pt;">&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_7a4d16a7_9bd9_4cc5_9f75_649d3ad88144"></a><a id="Tc_o2O9RDGpLkGj2kam0dL2Zw_2_0"></a><a id="Tc_fQkOhCUT0UK59tjS1T-Qow_2_2"></a><a id="Tc_WfdsFzlGgkirMF9jYp7cRA_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr style="height:11.65pt;"><td style="vertical-align:top;width:32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" name="dei:Security12bTitle" id="Tc_wm98eUUhwUKraG-WvXuaNw_3_0"><span style="font-size:9pt;">Common Stock, par value $0.01 per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" name="dei:TradingSymbol" id="Tc_cXVVI9miTUqeXJypwSXRAw_3_2"><span style="font-size:9pt;">XNCR</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_0ZwT6tLpT0qnwWlnAkyIEA_3_4"><span style="font-size:9pt;">Nasdaq Global Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 360pt;"><span style="font-size:10pt;">Emerging growth company&#160;</span><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_DqH_DPocvUqpt5F33XdJhg"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Wingdings';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Wingdings';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Wingdings';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_aabefa66_eb81_4333_a0ab_fae3224200bd"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item 1.01. Entry into a Material Definitive Agreement.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On October 1, 2021, Xencor, Inc. (&#8220;Xencor&#8221;) entered into a Collaboration and License Agreement (the &#8220;Agreement&#8221;) with Janssen Biotech, Inc. (&#8220;Janssen&#8221;) pursuant to which Xencor granted Janssen an exclusive worldwide license to develop, manufacture and commercialize plamotamab and pursuant to which Xencor and Janssen will conduct research and development activities to discover novel CD28 bispecific antibodies. The parties will conduct joint research activities for up to a two-year period to discover XmAb&#174; bispecific antibodies against CD28 and undisclosed B cell tumor-targets with Janssen receiving exclusive worldwide rights, subject to certain Xencor opt-in rights, to develop, manufacture and commercialize pharmaceutical products that contain one or more of such discovered antibodies (&#8220;CD28 Licensed Antibodies&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Under the terms of the Agreement, Xencor will receive a $100 million upfront payment. Johnson &amp; Johnson Innovation-JJDC, Inc., will also purchase $25 million of newly issued unregistered shares of Xencor common stock, priced at a 30-day volume-weighted average price of $33.4197 per share. The 748,062 shares of common stock will be subject to customary resale restrictions pursuant to Rule 144 of the Securities Act of 1933.  In addition, Xencor is eligible to receive milestone payments and royalties on net sales as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:10pt;line-height:1.28;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:left;">Plamotamab</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">. Xencor is eligible to receive up to $517.5 million in milestone payments, including $257.5 million in development and regulatory milestones and $260 million in sales milestones, as well as tiered royalties in the mid-teen to low-twenties percent range on net sales of products containing plamotamab, including CD28/plamotamab combination products developed under the agreement.<br /></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:left;">CD28 Licensed Antibodies.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;"> Xencor is eligible to receive up to $670 in milestone payments, including $410 million in development and regulatory milestones. For any products containing CD28 Licensed Antibodies, but excluding CD28/plamotamab combination products, Xencor is eligible to receive up to a total of $260 million in sales milestones, as well as tiered royalties in the high-single digit to low-double digit percent range on net sales.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">Xencor will collaborate with Janssen on further clinical development of plamotamab with Janssen paying 80% and Xencor paying 20% of costs, including those for a subcutaneous formulation. Xencor will continue, at its own expense, the previously announced clinical collaboration to evaluate the combination of plamotamab, tafasitamab and lenalidomide in patients with B-cell lymphoma, after which Janssen may opt into cost sharing to further develop the combination after establishing proof-of-concept. Xencor has the right to perform additional clinical studies of plamotamab/tafasitamab combinations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Xencor is generally responsible for conducting research activities under the Agreement, and Janssen is generally responsible for all development, manufacturing and commercialization activities for CD28 Licensed Antibodies that are advanced. Independent of plamotamab development activities, upon clinical proof-of-concept for a CD28 Licensed Antibody that is being developed outside of a plamotamab combination, Xencor has the right to opt-in to fund 15% of development costs and, if it opts-in to fund such development costs, to perform up to 30% of the detailing efforts in the United States. Xencor would then be instead eligible for low-double digit to mid-teen percent royalties on net sales of those products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk82787002"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The term of the Agreement will continue on a country-by-country basis and a product-by-product basis until there are no remaining royalty payment obligations from Janssen to Xencor. Janssen may terminate the Agreement in its entirety or solely with respect to plamotamab by providing prior written notice. Xencor may terminate the Agreement solely with respect to plamotamab if Janssen materially breaches 1) the diligence requirements for the development of plamotamab, or 2) if following receipt of commercial approval, commercially reasonable efforts to commercialize plamotamab products developed under the Agreement, if such material breach has not been cured within a defined period.<span style="font-size:11pt;"> </span>Xencor may terminate the Agreement solely with respect to Licensed CD28 Products if Janssen permanently discontinues all development activities prior to marketing approval.<span style="font-size:11pt;"> </span>Either party may also terminate the Agreement with written notice upon a bankruptcy of the other party or for a material breach by the other party if such breach has not been cured within a defined period of receiving such notice. In the event of a termination of any individual collaboration product or the Agreement in its entirety, certain rights revert to Xencor. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';">The Agreement contains customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act, and customary indemnification obligations by each of Xencor and Janssen against certain losses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The foregoing description of the Agreement does not purport to be complete and is subject to, and is qualified in its entirety by, the full text of the Agreement, a copy of which will be filed as an exhibit to Xencor&#8217;s Annual Report on Form 10-K for its fiscal year ending December 31, 2021, portions of which may be subject to FOIA Confidential Treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item 8.01 Other Events.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On October 4, 2021, Xencor issued a press release announcing the Agreement, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">(d)&#160;Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:87.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:3.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:87.9%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:87.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;" href="xncr-20211001xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Press release issued by Xencor, Inc. on October 4, 2021</span></a>. </p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:3.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.9%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:3.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cover Page Interactive Data File, formatting Inline Extensible Business Reporting Language (iXBRL).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:23.1pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date: October 4, 2021</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">XENCOR,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Celia Eckert</p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Celia Eckert</p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General Counsel &amp; Corporate Secretary</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>xncr-20211001xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 10/4/2021 05:09:51 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt;"><img src="xncr-20211001xex99d1001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="display:inline-block;height:40.05pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:151.5pt;"></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Xencor Enters Global Collaboration and License Agreement with Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients with B-Cell Malignancies</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">-- Second agreement with Janssen on bispecific antibodies directed toward the CD28 co-stimulatory receptor on T cells --</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">-- Xencor to receive $100 million upfront payment and $25 million equity investment and is eligible for a mid-teen to low-twenties percent royalty for plamotamab and potential milestone payments up to $1.188 billion --</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">-- Xencor management to host conference call today at 8:00 a.m. ET (5:00 a.m. PT) --</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">MONROVIA, Calif.--October 4, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced an exclusive collaboration and worldwide license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, to develop and commercialize plamotamab and novel XmAb</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> B-cell targeting bispecific antibodies that are designed to conditionally activate T cells through the CD28 co-stimulatory receptor. Plamotamab is a CD20 x CD3 XmAb bispecific antibody and is currently completing a Phase 1 dose-escalation study in patients with CD20-expressing hematologic malignancies.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;The treatment landscape in B-cell lymphoma will potentially be redefined by CD20 x CD3 bispecific antibodies, such as plamotamab, and the best outcomes for patients will require creative combination approaches using complementary mechanisms of action. We are delighted to collaborate with Janssen&#8217;s leading scientists to expand the scope of the plamotamab program, particularly as we explore opportunities to combine with novel B-cell targeted CD28 bispecific antibodies that can potentially selectively enhance T-cell cytotoxic activity,&#8221; said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. &#8220;This collaboration complements our plans to initiate combination clinical trials of plamotamab with tafasitamab and lenalidomide, and it expands our strategy to develop multiple highly active chemotherapy-free regimens for B-cell cancers.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Under the terms of the agreement, Janssen will receive worldwide exclusive development and commercialization rights to plamotamab, whether as a monotherapy or in combination regimens</font><font style="font-size:11pt;"><a name="_Hlk82416485"></a></font><font style="font-family:'Arial','Helvetica','sans-serif';">. Xencor will collaborate with Janssen on further clinical development of plamotamab with Janssen paying 80% and Xencor paying 20% of costs,</font><font style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> including those for a subcutaneous formulation anticipated to enter clinical trials in 2022. In parallel, Xencor will continue, at its own expense, a previously announced clinical collaboration to evaluate the combination of plamotamab, tafasitamab and lenalidomide in patients with B-cell lymphoma, including a Phase 2 trial in relapsed or refractory diffuse large B-cell lymphoma anticipated to start in late 2021 or early 2022.   </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Further, Xencor will apply its XmAb bispecific Fc technology to create and characterize XmAb CD28 bispecific antibody candidates against B-cell targets during a two-year joint research collaboration, and Janssen will have an exclusive worldwide license to develop selected molecules in combination with plamotamab and other agents, such as CD3 bispecific antibodies.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Xencor will receive an upfront payment of $100 million, and Johnson &amp; Johnson Innovation - JJDC, Inc. will purchase $25 million of newly issued shares of Xencor common stock. Xencor will be eligible to receive up to $1.188 billion in potential development, regulatory and sales milestone payments, as well as tiered royalties on net sales of products developed under the agreement, ranging from mid-teen to low-twenties percentages for products containing plamotamab and plamotamab/CD28 bispecific antibody combinations. Separate terms apply to CD28 bispecific antibodies commercialized outside of a plamotamab combination, where Xencor retains an option to co-fund development costs in exchange for higher royalties and the right to co-detail such products in the United States.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The agreement is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act, and closing is expected to occur in the fourth quarter of 2021.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Conference Call</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Xencor management will host a conference call today at 8:00 a.m. ET (5:00 a.m. PT) to discuss the agreement.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The live call may be accessed by dialing (877) 359-9508 for domestic callers or +1 (224) 357-2393 for international callers and referencing conference ID number 8580556. A live webcast of the conference call will be available online from the Investors section of Xencor&#39;s website at </font><font style="font-family:'Arial','Helvetica','sans-serif';">www.xencor.com</font><font style="font-family:'Arial','Helvetica','sans-serif';">. The call will be archived on Xencor&#39;s website for 30 days.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About Plamotamab</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Plamotamab is an investigational tumor-targeted XmAb</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> bispecific antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3). CD20 is highly expressed across a range of B-cell tumors, including non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Engagement of CD3 by plamotamab activates T cells for highly potent and targeted killing of CD20-expressing tumor cells. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Plamotamab is currently being evaluated in a Phase 1 clinical study for the treatment of patients with CD20-expressing hematologic malignancies, including NHL and CLL. Preliminary safety and anti-tumor activity from the Phase 1 study indicated that plamotamab was generally well tolerated and demonstrated encouraging clinical activity as a monotherapy.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About XmAb</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"> CD28 Bispecific Antibodies</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">CD28 bispecific antibodies are a class of T cell engager designed to synergize with and complement, in a tumor-specific manner, other mechanisms of T cell activation, such as checkpoint inhibitors and CD3 bispecific antibodies. CD28 is a key immune co-stimulatory receptor on T cells that historically has proved difficult to engage therapeutically. Xencor has engineered XmAb</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> bispecific antibodies, targeting CD28 with one binding domain and tumor cells with a second binding domain, that have demonstrated tumor-dependent T-cell activity in preclinical testing. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;">Xencor announced its first collaboration with Janssen to discover a CD28 bispecific antibody against an undisclosed prostate tumor target in 2020. Xencor&#8217;s lead CD28 bispecific program, XmAb808, targets B7-H3 for potential use against a wide range of tumor types and is expected to start clinical development in 2022.  </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About Xencor, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor&#39;s XmAb</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> technology are in clinical development internally and with partners. Xencor&#39;s XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit </font><font style="font-family:'Arial','Helvetica','sans-serif';">www.xencor.com</font><font style="font-family:'Arial','Helvetica','sans-serif';">.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Certain statements contained in this press release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements that are not purely statements of historical fact, and can generally be identified by the use of words such as &#8220;potential,&#8221; &#8220;can,&#8221; &#8220;will,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;seek,&#8221; &#8220;look forward,&#8221; &#8220;believe,&#8221; &#8220;committed,&#8221; &#8220;investigational,&#8221; and similar terms, or by express or implied discussions relating to Xencor&#8217;s business, including, but not limited to, statements regarding the receipt of milestone payments and royalties; the quotations from Xencor&#39;s president and chief executive officer and other statements that are not purely statements of historical fact. Such statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Xencor and are subject to significant known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics, the existence of current or future facts or circumstance that may prevent or delay the closing of the transaction and other risks described in Xencor&#39;s public securities filings. For a discussion of these and other factors, please refer to Xencor&#39;s annual report on Form 10-K for the year ended December 31, 2020 as well as Xencor&#39;s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended to date. All forward-looking statements are qualified in their entirety by this cautionary statement and Xencor undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Contacts</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Charles Liles</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">cliles@xencor.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Media Contact</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Jason I. Spark</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Canale Communications</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">619-849-6005</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">jason@canalecomm.com</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>xncr-20211001xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 xncr-20211001xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Y = # 2(  A$! Q$!_\0
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M^G**^;K#Q[XGT]\QZO<2KW6X/F@_]]9_2N_\-?%J"[E6VUV%;9VP%N(_N?\
M AV^M*5*2''$1D>I49J*-TD171@R, 58'((]:D[5F;W"BO(=5^+6IV&KWMDF
MG6C);W$D09BV2%8C/7VJI_PN;5O^@99_]]/_ (UI[.1C[>%['M-%<=XB\>V7
MA[2X))%$VH3Q+(ELAQC(ZD]A7E&J?$;Q+J;G%^UI&3PEM\F/^!#YOUHC3DPG
M7C$^B:*^9[;QEXEM)1)'K=\S#M+,9!^39%=SX:^+<OG);:_&IC;C[5$N-O\
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MK\4,=O$D44:QQH,*B#  ] *<ZG,B*-%P=[DM%%%9G0%(:6D- '#_ !&\6_\
M"/Z3]DM9 -0NE*I@\QIW;^@_^M7@I)+$DDD]2:Z3Q_<37/C?4S,3E)-B@]E
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MC-THMW([6UALK:.WMXECAB4*B*.% [5-12U)I:P4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>xncr-20211001.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/4/2021 5:09:44 PM-->
<!--Modified on: 10/4/2021 5:09:44 PM-->
<xsd:schema targetNamespace="http://www.xencor.com/20211001" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xncr="http://www.xencor.com/20211001" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.xencor.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="xncr-20211001_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="xncr-20211001_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>xncr-20211001_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/4/2021 5:09:44 PM-->
<!--Modified on: 10/4/2021 5:09:44 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>xncr-20211001_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/4/2021 5:09:44 PM-->
<!--Modified on: 10/4/2021 5:09:44 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="xncr-20211001.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.xencor.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.xencor.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637689641845854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637689641845854098" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637689641845854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637689641845854098" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637689641845854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637689641845854098" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637689641845854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637689641845854098" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637689641845854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637689641845854098" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637689641845854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637689641845854098" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637689641845854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637689641845854098" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637689641845854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637689641845854098" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637689641845854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637689641845854098" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637689641845864120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637689641845864120" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637689641845864120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637689641845864120" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637689641845864120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637689641845864120" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637689641845864120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications_637689641845864120" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637689641845864120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial_637689641845864120" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637689641845864120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_637689641845864120" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637689641845864120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637689641845864120" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637689641845864120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637689641845864120" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637689641845864120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637689641845864120" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637689641845864120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637689641845864120" order="19" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637689641845864120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637689641845864120" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637689641845864120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637689641845864120" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637689641845874109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637689641845874109" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>xncr-20211001x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="xncr-20211001.xsd" xlink:type="simple"/>
    <context id="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326732</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Tc_gphqhG1GeUuh2NS0KI5ZEA_2_1">0001326732</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Tc_5_LMAeMA3kubrPNLCC93zw_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Narr_EDgK3i7Lx0atiQxZaALo0g">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Narr_yY-OjCvTEEaezaiwstrwnQ">2021-10-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Narr_XIZcNPqU2kadIe1iep93Hw">XENCOR,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Tc_9SAcT6RcHEuQy8mVbOnESw_2_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Tc_0-adsj4q60-JTb294GIMqw_2_2">001-36182</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Tc_r5z8mT8tA0iFffIfF5lebw_2_4">20-1622502</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Narr_Din-X3k4m0SRcR0AFp3zgg">111 West Lemon Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Narr_UDp-RF92SkqEchcbkh1MFw">Monrovia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Narr_AfHr_9oTaEeCKFIu96deWg">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Tc_CskCa4pPekekgp4I9cvelw_1_1">91016</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Narr_Ms8OguH7802T47BNJetrQQ">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Narr_T1uPBKMnR0mYndl3f5r-FQ">305-5900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Narr_UCw0dtQqhU6hxQ_c5bipfw">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Narr_LrbClwsJMEm84IFytWhLGA">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Narr_HZMxVBmQR02kT6EwJWggTA">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Narr_9TOKdo-vnECAnT9IzMMrCQ">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Tc_wm98eUUhwUKraG-WvXuaNw_3_0">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Tc_cXVVI9miTUqeXJypwSXRAw_3_2">XNCR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Tc_0ZwT6tLpT0qnwWlnAkyIEA_3_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ"
      id="Narr_DqH_DPocvUqpt5F33XdJhg">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140579011869336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  01,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">XENCOR,&#160;INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-1622502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">111 West Lemon Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Monrovia<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">305-5900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XNCR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001326732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #/:413'#AEZC\!   \ @
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M>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ SVE$4R0>FZ*M
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #/:413 &=]->X    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #/
M:413F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( ,]I1%/Z41Y\-P0  &$0   8
M  " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #/
M:413GZ ;\+$"  #B#   #0              @ %Z#   >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( ,]I1%.7BKL<P    !,"   +              "  58/
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,]I1%,<.&7J/P$  #P"   /
M          "  3\0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #/:413
M)!Z;HJT   #X 0  &@              @ &K$0  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " #/:41399!YDAD!  #/ P  $P
M        @ &0$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"
(  #:$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="xncr-20211001x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xencor.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="xncr-20211001x8k.htm">xncr-20211001x8k.htm</File>
    <File>xncr-20211001.xsd</File>
    <File>xncr-20211001_lab.xml</File>
    <File>xncr-20211001_pre.xml</File>
    <File>xncr-20211001xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "xncr-20211001x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "xncr-20211001x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "xncr-20211001_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xncr-20211001_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "xncr-20211001.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "xncr",
   "nsuri": "http://www.xencor.com/20211001",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xncr-20211001x8k.htm",
      "contextRef": "Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.xencor.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xncr-20211001x8k.htm",
      "contextRef": "Duration_10_1_2021_To_10_1_2021_ubyS8lV4zUGaGC_-AlpngQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.xencor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001558370-21-012970-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-012970-xbrl.zip
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MOT_:__".?=FD"P':VP9J>VJYW@F-7M'!M-.FZ102 ]:"C1Q3X+^?G<0I2>W
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M."S?)$W3J4HO*L[QZI)OW9KHX-Z<3@UPY"+;"P5-'.JS_\ U)M;44TU.;+P
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M,2YX<V102P$"% ,4    " #/:413:/P])FX%  #T.P  %0
M@ &C P  >&YC<BTR,#(Q,3 P,5]L86(N>&UL4$L! A0#%     @ SVE$4P-A
M=VV(!   DB8  !4              ( !1 D  'AN8W(M,C R,3$P,#%?<')E
M+GAM;%!+ 0(4 Q0    ( ,]I1%-1SE\A>1T  $#8   4              "
M ?\-  !X;F-R+3(P,C$Q,# Q>#AK+FAT;5!+ 0(4 Q0    ( ,]I1%-&\D=#
M+A,  -YA   8              "  :HK  !X;F-R+3(P,C$Q,# Q>&5X.3ED
;,2YH=&U02P4&      4 !0!- 0  #C\

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
